Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month.
The company reported its 2022 forecast in its quarterly earnings report, which showed that Pfizer made almost $24 billion in revenue in the final quarter of 2021. About half of that came from sales of its COVID-19 vaccine and $76 million from sales of its antiviral treatment Paxlovid, which was the first COVID-19 treatment pill authorized in the United States.
The Food and Drug Administration (FDA) asked a federal judge on Nov. 15 to give it until the year 2076 to fully release the documents in its possession tied to the approval of the Pfizer-BioNTech COVID-19 vaccine.
